Drugs Made In America Acquisition Corp. Rights(DMAAR)
USD --+0.00%
Reward52Moderate
Risk42Moderate
📊25%Data
DMAAR
+0.0 · +0.00%
USD · NASDAQ
Drugs Made In America Acquisition Corp. Rights |
Balanced
Market Cap:2.45M
ℹ️
Reward Rating
52
Moderate
Bottom 50% (model universe)
25% data coverage
ℹ️
Risk Rating
42
Moderate
Risk Assessment
50% data coverage
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on DMAAR to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Drugs Made In America Acquisition Corp. Rights?

Drugs Made In America Acquisition Corp.

DMAAR · Verdict

Moderate reward · moderate risk

DMAAR leads on volatility with the rest of the factors in line with peers.

Based on 38% data coverage

DMAAR · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Drugs Made In America Acquisition Corp. Rights?

Drugs Made In America Acquisition Corp. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses. The company is listed on the NASDAQ in USA, with a market capitalisation of 2.45M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Adequate profitability with some margin variability in recent periods.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (52)

The scoring profile indicates limited reward potential at this time, with valuation and growth offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorN/A
Market Cap2.45M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.2433
52 Week Low0.0902
Last AnnualN/A
IPO Date2/25/2025
IncorporatedUSA
Shares Outstanding20M
No. of EmployeesN/A
IndustryN/A
ExchangeNASDAQ
BetaN/A
CurrencyUSD